Loading...
•
Dec 31, 2024
Ocular Therapeutix Q4 2024 Earnings Report
Ocular Therapeutix reported a wider net loss for Q4 2024, with increased revenues and higher R&D expenses.
Key Takeaways
Ocular Therapeutix saw revenue growth in Q4 2024 but reported a higher net loss due to increased research and development expenses. The company maintains a strong cash position and does not plan to raise additional capital in 2025.
Revenue increased to $17.1 million in Q4 2024, up from $14.8 million in Q4 2023.
Net loss widened to $48.4 million due to increased R&D expenses.
Cash balance reached $392.1 million, expected to fund operations into 2028.
No plans to raise additional capital this year.
Ocular Therapeutix
Ocular Therapeutix
Ocular Therapeutix Revenue by Segment
Revenue by Segment
Product Revenue
CapyFin.comCollaboration Revenue
CapyFin.com Forward Guidance
Ocular Therapeutix remains focused on advancing its pipeline while maintaining a strong cash position, with upcoming regulatory milestones expected in 2025.
Positive Outlook
- Cash balance expected to fund operations into 2028.
- No plans to raise additional capital in 2025.
- Regulatory feedback for AXPAXLI in NPDR and DME expected in 1H 2025.
- Strong retention rates in SOL-1 trial for wet AMD.
- Potential accelerated registration timelines due to SOL-1 and SOL-R adjustments.
Challenges Ahead
- Net loss increased significantly due to rising R&D costs.
- Higher operating expenses impact profitability.
- SOL-1 trial primary endpoint data delayed to Q1 2026.
- Revenue growth offset by higher gross-to-net provisions.
- Continued need for substantial investment in clinical trials.
Revenue & Expenses
Visualization of income flow from segment revenue to net income